Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-life management of atopic dermatitis patients with an inadequate response to on-label use of dupilumab.
Strizzolo R, Seneschal J, Soria A, Staumont-Sallé D, Barbarot S, Viguier M, Jachiet M, Nosbaum A, Clément A, Tauber M, Mallet S, Du-Thanh A; French Atopic Dermatitis Network from the GREAT Research group. Strizzolo R, et al. Among authors: staumont salle d. World Allergy Organ J. 2024 Jul 4;17(7):100923. doi: 10.1016/j.waojou.2024.100923. eCollection 2024 Jul. World Allergy Organ J. 2024. PMID: 39157196 Free PMC article.
Sexuality impairment in patients with atopic dermatitis.
Misery L, Seneschal J, Corgibet F, Halioua B, Sampogna F, Merhand S, Skayem C, Hayoun YB, Taieb C, Staumont-Sallé D, Ezzedine K, Richard MA. Misery L, et al. Among authors: staumont salle d. Clin Exp Dermatol. 2024 Sep 4:llae360. doi: 10.1093/ced/llae360. Online ahead of print. Clin Exp Dermatol. 2024. PMID: 39229930 No abstract available.
Switching From Dupilumab to Tralokinumab or Janus Kinase Inhibitors in Cases of Ocular and/or Facial Adverse Events in Patients With Atopic Dermatitis: A Multicenter Retrospective Study.
Beyrouti A, Deuze J, Fontas E, Foureau A, Barbarot S, Aubert H, Bernier C, Le Moigne M, Passeron T, Boukari F, Garnier M, Jachiet M, Tetart F, Seneschal J, Toussaint C, Mahé E, Leleu C, Regnault MM, Pasteur J, Nosbaum A, Badaoui A, Fougerousse AC, Pralong P, Viguier M, Droitcourt C, Abasq C, Mallet S, Raison-Peyron N, Staumont-Sallé D, Hubiche T; French Atopic Dermatitis Network (FRADEN) from the Groupe de Recherche sur l’Eczéma Atopique (GREAT) Research Group. Beyrouti A, et al. Among authors: staumont salle d. J Allergy Clin Immunol Pract. 2024 Dec 12:S2213-2198(24)01241-8. doi: 10.1016/j.jaip.2024.12.001. Online ahead of print. J Allergy Clin Immunol Pract. 2024. PMID: 39672377
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Simpson EL, et al. N Engl J Med. 2016 Dec 15;375(24):2335-2348. doi: 10.1056/NEJMoa1610020. Epub 2016 Sep 30. N Engl J Med. 2016. PMID: 27690741 Free article. Clinical Trial.
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis.
Simpson EL, de Bruin-Weller M, Hong HC, Staumont-Sallé D, Blauvelt A, Eyerich K, Gooderham M, Shahriari M, Mallbris L, Atwater AR, Rueda MJ, Ding Y, Liu Z, Agell H, Silverberg JI. Simpson EL, et al. Dermatol Ther (Heidelb). 2024 May;14(5):1145-1160. doi: 10.1007/s13555-024-01158-4. Epub 2024 May 3. Dermatol Ther (Heidelb). 2024. PMID: 38700646 Free PMC article.
Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.
Bissonnette R, Warren RB, Pinter A, Agner T, Gooderham M, Schuttelaar MLA, Crépy MN, Stingeni L, Serra-Baldrich E, Baranowski K, Korn S, Kurvits M, Plohberger U, Strange Vest N, Schliemann S; trial investigators. Bissonnette R, et al. Lancet. 2024 Aug 3;404(10451):461-473. doi: 10.1016/S0140-6736(24)01027-4. Epub 2024 Jul 18. Lancet. 2024. PMID: 39033766 Clinical Trial.
Hypereosinophilia and Hypereosinophilic Syndromes: First Findings From a Nationwide Multicenter Cohort.
Lefèvre G, Bleuse S, Puyade M, Moulis G, Néel A, Abisror N, Baudet A, Bonnotte B, Dion J, Dossier A, Grall M, Lifermann F, Limal N, Lioger B, Machelart I, Mohr C, Outh R, Queyrel-Moranne V, Slama B, Tréfond L, Abou Chahla W, Ackerman F, Belfeki N, Berezne A, Blade JS, Bouderbala MA, Chebrek S, Cottin V, De Almeida S, De Masson A, Dezoteux F, Goulenok T, Jachiet V, Jouvray M, Latu I, Ledoult E, Leurs A, Lugosi M, Martin M, Melboucy-Belkhir S, Morati-Hafsaoui C, Quemeneur T, Rohmer J, Roy-Peaud F, Sanges S, Schleinitz N, Staumont-Salle D, Taillé C, Terriou L, Tieulie N, Koenga JDE, Schwarb L, Panel K, Kahn JE, Groh M; COHESion study group. Lefèvre G, et al. Among authors: staumont salle d. Allergy. 2025 Jan 5. doi: 10.1111/all.16463. Online ahead of print. Allergy. 2025. PMID: 39757773
Oncostatin-M Is Produced by Human Eosinophils and Expression Is Increased in Uncontrolled Severe Asthma.
Esnault S, Bernau K, Floerke HL, Dendooven A, Delaunay E, Dill-McFarland KA, Altman MC, Busse WW, Rosenkranz MA, Tattersall MC, Johansson MW, Labreuche J, Beury D, Sebda S, Dezoteux F, Segard B, Mortuaire G, Staumont-Sallé D, Stoup T, Chenivesse C, Sandbo N, Jarjour NN, Lefèvre G. Esnault S, et al. Among authors: staumont salle d. Allergy. 2024 Dec 21. doi: 10.1111/all.16453. Online ahead of print. Allergy. 2024. PMID: 39707874 No abstract available.
137 results